Wahl, R.I., Siegel, B.A., Coleman, R.E. and Gatsonis, D.G. (2004) Prospective Multicenter Study of Axillary Nodal Staging by PET in Breast Cancer. A Report of the Staging Breast Cancer with PET Study Group. Journal of Clinical Oncology, 22, 277-285.
https://doi.org/10.1200/JCO.2004.04.148

has been cited by the following article:

• TITLE: The Role of 18F-FDG PET/CT in Staging Breast Carcinoma in Hanoi Oncology Hospital, Vietnam

  AUTHORS: Cuong Duy Dang, Thang Van Nguyen, Tuynh Van Chu, Huy Quang Pham

  KEYWORDS: 18F-FDG PET/CT (Positron Emission Tomography with 2-Deoxy-2-[Fluorine-18]Fluoro-D-Glucose Integrated with Computed Tomography), Breast Carcinoma, Staging, SUV (Standardized Uptake Value)

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.10 No.1, January 27, 2022

  ABSTRACT: Purpose: This study aimed to evaluate the role of 18F-FDG PET/CT scans in staging breast carcinoma. Materials and Methods: A descriptive study on 46 patients who were diagnosed with breast carcinoma in Hanoi Oncology Hospital, Vietnam from June 2019 to June 2021. Those patients underwent 18F-FDG PET/CT scans for pre-treatment staging. Results: There was a positive correlation between the size of primary tumors and their SUV (p 18F-FDG PET/CT were 75% and 100%, respectively. The rate of distant metastasis detection was 15.2% (7/46 patients). Metastatic lesions were found in bone, lungs, liver, and lymph nodes. There was a significant difference in SUV among organs (p 18F-FDG PET/CT. After PET/CT, 17.4% patients (8/46) had their treatment plan changed. Conclusions: 18F-FDG PET/CT plays an important role in staging breast carcinoma. Determining accurately the breast carcinoma stage by 18F-FDG PET/CT could help alter treatment strategy to best suit with patients, and avoid unnecessary surgery.